Transfection of Exogenous Fibroblast Growth Factor (FGF) on Human Embryonic Stem Cells (ESCs) as a Regenerative Agent for Patients with Type 1 Diabetes Mellitus (T1DM)
نویسندگان
1 Endocrinology and Metabolism Division, Department of Internal Medicine, Medical Faculty of Udayana University/Sanglah Hospital, Denpasar, Bali, Indonesia
2 Medical Faculty of Udayana University, Denpasar, Bali, Indonesia
3 Medical Faculty of Udayana University, Denpasar, Bali, Indonesia
4 Medical Faculty of Udayana University, Denpasar, Bali, Indonesia
doi
10.30491/ijmr.2020.219730.1077چکیده
Type 1 Diabetes Mellitus (T1DM) is an autoimmune disorder which results in the INS pancreatic β-cell destruction and contributes to around 5 to 10% of all diabetes mellitus cases, especially in children. At the moment, the only treatment for T1DM is by insulin injection, which is injected in order to prevent the complication of T1DM. However, several studies have shown that combination between Embryonic Stem Cells (ESCs) and the Fibroblast Growth Factor 2 (FGF-2) may be a successful modality to treat T1DM. Actually, the ESCs may become the potential therapy in treating T1DM.
